On Medicare Advantage Plan[s] Enrollment

Posted on June 3, 2015 by Dr. David Edward Marcinko MBA MEd CMP™

Join Our Mailing List

Medicare Pre-Paid Enrollee Composition

By http://www.MCOL.com

***

medicare advantage

***

NOTE: CMS Releases 2013 Hospital, Physician Data

***

The opening of this week’s Health Datapalooza conference in Washington was the setting for a new Medicare data dump on physician and hospital inpatient/outpatient payment and utilization rates. This is the third annual release of data as part of the Obama administration’s information transparency initiative to promote increased quality of care and more informed healthcare spending by consumers. A link to the inpatient dataset is here, the outpatient dataset is here, and the physician / supplier dataset is here.

Source: Joseph Goedert, Health Data Management [6/2/15]

***

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

Product DetailsProduct Details

Filed under: Health Insurance | Tagged: , , , | 10 Comments »

On Non-Financial Conflicts of Interest

Posted on June 3, 2015 by Dr. David Edward Marcinko MBA MEd CMP™

Join Our Mailing List

Devastating?

Austin Frakt PhD[By Austin Frakt PhD]

Noam Schieber’s NYT piece today is devastating.

About selecting papers to be most prominently featured at a top economics conference, David Card is quoted,

“‘I choose papers that are going to be written up’ in the mainstream press. […] ‘It’s what the people want.’”

via Non-financial conflicts of interest.

***

Censure

***

Channel Surfing

Have you visited our other topic channels? Established to facilitate idea exchange and link our community together, the value of these topics is dependent upon your input. Please take a minute to visit. And, to prevent that annoying spam, we ask that you register.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Assessment

Has this philosophy seeped into medicine, the financial services industry and health economics; etc?

Dr. David Edward Marcinko MBA

More: Another report casts skeptical eye on patient satisfaction surveys

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

Product DetailsProduct Details

Sponsors Welcomed

 And, credible sponsors and like-minded advertisers are always welcomed.

Support the “Medical Executive-Post”

***

UPDATE

Conflicts of interest, the NEJM, and where we go next

Posted: 04 Jun 2015 03:20 PM PDT

If you haven’t yet, take a look at Lisa Rosenbaum’s NEJM essays (here, here, and here) calling for new thinking about researchers and financial conflicts of interest. The essays are nuanced and go against the grain of much recent writing on research ethics.

Rosenbaum’s essays have generated many responses (the Lown Institute has collected some of them here). I examine Rosenbaum’s views in an essay in the New Republic. I’m sympathetic to many of her arguments, but I think we need more transparency in science, not less (see also here). Austin explores her views here, here, and here. Rosenbaum has elicited some exceptionally harsh rejoinders, including one from two former editors-in-chief of the NEJM.

This discussion has been intense because the stakes are very high. If manipulated research data allow bad drugs to enter the market, people can die. Conversely, if unjustified prejudice against industry slows the progress of research, that could kill people too.

@Bill_Gardner

Filed under: Ethics, Experts Invited, Health Economics | Tagged: , , | Leave a comment »